On Wednesday, ACADIA Pharmaceuticals ACAD will release its latest earnings report. Here is Benzinga's outlook for the company.
Earnings and Revenue
ACADIA Pharmaceuticals EPS will likely be near a loss of 45 cents while revenue will be around $58.96 million, according to analysts.
In the same quarter last year, ACADIA Pharmaceuticals announced an EPS loss of 55 cents on revenue of $30.47 million. Sales would be up 93.47 percent on a year-over-year basis. Here's how the company's EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | -0.56 | -0.58 | -0.62 | -0.72 |
| EPS Actual | -0.44 | -0.55 | -0.53 | -0.55 |
Stock Performance
Over the last 52-week period, shares are down 53.76 percent. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. Analysts generally rate ACADIA Pharmaceuticals stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
ACADIA Pharmaceuticals is scheduled to hold a conference call at 8:00 a.m. ET and it can be accessed here: http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-calendar
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
